Kezar Life Sciences Balance Sheet Health
Financial Health criteria checks 5/6
Kezar Life Sciences has a total shareholder equity of $134.0M and total debt of $10.3M, which brings its debt-to-equity ratio to 7.7%. Its total assets and total liabilities are $164.1M and $30.0M respectively.
Key information
7.7%
Debt to equity ratio
US$10.26m
Debt
| Interest coverage ratio | n/a |
| Cash | US$148.39m |
| Equity | US$134.05m |
| Total liabilities | US$30.04m |
| Total assets | US$164.09m |
Recent financial health updates
Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?
Dec 08
Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?
Aug 15Recent updates
Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?
Dec 08FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment
Oct 03Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?
Aug 15Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02
Aug 11Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case
Jul 27Kezar Life Sciences appoints Nick Mordwinkin as chief business officer
Jul 11We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Jan 03Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation
Aug 26We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Apr 05Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like
Mar 01Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings
Jan 25Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans
Dec 21
Kezar Life Sciences selected for the Nasdaq Biotechnology Index
Dec 14Financial Position Analysis
Short Term Liabilities: KZR's short term assets ($156.4M) exceed its short term liabilities ($20.4M).
Long Term Liabilities: KZR's short term assets ($156.4M) exceed its long term liabilities ($9.6M).
Debt to Equity History and Analysis
Debt Level: KZR has more cash than its total debt.
Reducing Debt: KZR's debt to equity ratio has increased from 0% to 7.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KZR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KZR has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 23.4% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 12:33 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kezar Life Sciences, Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Maurice Raycroft | Jefferies LLC |
| Catherine Novack | JonesTrading Institutional Services, LLC |